EXAI Stock Overview
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs.
Exscientia plc Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$8.21|
|52 Week High||US$30.38|
|52 Week Low||US$6.56|
|1 Month Change||-15.19%|
|3 Month Change||-27.28%|
|1 Year Change||-69.71%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-69.71%|
Recent News & Updates
The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts
Today is shaping up negative for Exscientia plc ( NASDAQ:EXAI ) shareholders, with the analysts delivering a...
Exscientia: Using AI To Power Drug Development
Today, we take our first look at Exscientia, a unique developmental concern using artificial intelligence or AI to help identify promising drug compounds. Its platform has drawn numerous collaboration deals from the likes of Sanofi and Bristol-Myers Squibb. An investment analysis follows in the paragraphs below. It's not treason if you win. ― Lisa Shearin, Bewitched & Betrayed Today, we put Exscientia (EXAI) in the spotlight for the first time. The developmental biotech concern has a fairly unique method of drug discovery and is headquartered across the pond. The shares came public less than a year ago but are not in 'Busted IPO' territory. What lies ahead for Exscientia? An analysis follows below. Seeking Alpha Company Overview Exscientia is located in Oxford in the United Kingdom. The company is focused on developing small molecule drug candidates. Exscientia's AI developmental platform enables it to design candidate drug molecules, as well as to provide patients with drug therapies. The firms provides end-to-end solution of AI and technologies for target identification, drug candidate design, translational models, and patient selection. The stock currently trades under $13.00 a share and sport a market capitalization just under $1.6 billion. June Company Presentation The company is bringing together a team of industry scientists and technologists which are looking to streamline the drug discovery process by extensively using AI to design and develop better molecules. June Company Overview The company has numerous collaboration partners including Bristol-Myers Squibb Company (BMY), the Bill & Melinda Gates Foundation, and Sanofi (SNY), which came on board this year. June Company Presentation In fact, the new partnership with Sanofi is the biggest news around Exscientia so far in 2022. This agreement provides for the development of up to 15 novel small molecule candidates across oncology and immunology in early January. June Company Presentation The deal provided a $100 million upfront payment to Exscientia which it recorded in April. The company can also earn up to $5.2 billion in additional milestone payments as well sales royalties in the high-single-digits to mid-teens. The agreement also provides an option for clinical co-investment by Exscientia to increase the royalty rate up to 21% on net sales of co-funded products. As can be seen below, this is one of many collaboration deals the company has in place. June Company Presentation Analyst Commentary & Balance Sheet Despite a market cap north of one and a half billion dollars, the company gets little intention from Wall Street. Most likely because of an overseas domicile. On June 13th, Morgan Stanley maintained its Equal Weight rating on the stock and lowered its price target a buck a share to $20. A month prior, Goldman Sachs had reissued its Buy rating and $20 price target on EXAI. That is the only analyst ratings I can find on the stock so far in 2022. June Company Overview Just over two percent of the stock's outstanding float is currently held short. The company ended the second quarter with nearly $720 million in cash and marketable securities after posting a GAAP net loss of -£0.41 a share in the quarter. The company only burned through a bit over $10 million in cash to fund all operations during the last quarter. Verdict The current analyst consensus has the company losing 90 cents a share on $69 million in revenue in FY2022. In FY2023, losses are expected to increase to nearly $1.50 a shares as revenues fall. It should be noted, that few firms have projections on Exscientia's and there is a very wide range to earnings and revenue estimates. Given that all revenues in coming year will come from either developmental milestones within existing collaboration deals or upfront payments from new collaboration agreements, one can't blame analyst firms for having a very difficult time modeling future revenue streams. June Company Presentation The company has made some good progress in showing that its AI enabled platform can more effectively identify promising early stage drug candidates. This is a key reason it has garnered an impressive list of collaboration partners.
|EXAI||US Biotechs||US Market|
Return vs Industry: EXAI underperformed the US Biotechs industry which returned -25.8% over the past year.
Return vs Market: EXAI underperformed the US Market which returned -21.5% over the past year.
|EXAI Average Weekly Movement||13.5%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: EXAI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: EXAI's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates.
Exscientia plc Fundamentals Summary
|EXAI fundamental statistics|
Is EXAI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EXAI income statement (TTM)|
|Cost of Revenue||UK£24.21m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.57|
|Net Profit Margin||-193.15%|
How did EXAI perform over the long term?See historical performance and comparison